Request a Representative

Your local representative can provide you with more information about AlphaNine SD.

Submit a request below.

All fields are required unless otherwise stated

Your details

First Name

Last Name

Occupation

Hospital/Facility or Corporation Name

ZIP Code

Your request

I would like information on:

* Check all that apply

AlphaNine SD

Ordering AlphaNine SD

Other

How would you like to be contacted?

I would like to be contacted by:

Phone call

Email

Additional comments

Leave your additional comments below (Optional)

0 characters left

I would like to receive future communications from Grifols (Optional)

Data Protection Information
The Grifols' group company to which you submit the request, as data controller, will process your personal data to provide information about our products. The legal basis is your consent. Your data may be shared with Grifols' group companies and other third parties. You have the right to access, rectify and erase, as well as any other rights detailed in the additional information. For additional information on personal data protection check here.

recaptcha-check Required

By clicking the button below, I agree to my data being used as described in this form.

Indication
AlphaNine® SD (coagulation factor IX [human]) is indicated for the prevention and control of bleeding in patients with Factor IX deficiency due to hemophilia B.

Important Safety Information

AlphaNine SD is made from human plasma. Plasma products carry a risk of transmitting infectious agents, including viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Incidences of thrombosis or disseminated intravascular coagulation (DIC) have been reported following administration of Factor IX Complex concentrates which contain high amounts of Factor II, VII, and X. AlphaNine SD contains low, nontherapeutic levels of Factor II, VII, and X.

Following administration in surgery patients and individuals with known liver disease, the physician should closely observe the patient for signs and symptoms of potential disseminated intravascular coagulation.

Allergic type hypersensitivity reactions, including anaphylaxis, have been reported for all factor IX products. The administration of plasma preparations may cause allergic reactions, mild chills, nausea or stinging at the infusion site.

Nephrotic syndrome has been reported following attempted immune tolerance induction with factor IX products in hemophilia B patients with factor IX inhibitors and a history of severe allergic reactions to Factor IX.

In order to minimize the possibility of thrombogenic complications, dosing guidelines should be strictly followed.

AlphaNine SD should not be administered at a rate exceeding 10 mL/ minute. Rapid administration may result in vasomotor reactions.

Please see full Prescribing Information for AlphaNine SD.